• Lexicon Pharmaceuticals (NASDAQ:LXRX) lost ~11% in the premarket on Friday after announcing plans to eliminate its commercial operations in a bid to generate as much as $100M in cost savings next year.
• The decision follows the FDA’s rejection of the company’s New Drug Application (NDA) for diabetes therapy, Zynquista (sotagliflozin), based on deficiencies found in the NDA.
• Accordingly, Lexicon’s (NASDAQ:LXRX) commercial field team will be axed, and 60% of the company’s workforce will lose their jobs.
• The size of the company’s other functions will also be reduced, and all ongoing and planned promotional efforts for its commercialized drugs, Inpefa and Zynquista, will also come to an end. Through the program, Lexicon (LXRX) plans to cut its 2025 operating costs by $100M.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。